NCT04616560: Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma |
|
|
| Suspended | 2 | 27 | US | Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516 | National Cancer Institute (NCI) | Osteosarcoma, Recurrent Osteosarcoma | 03/25 | 03/25 | | |
